Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Jun 26, 2013

166_ip_2013-06-26_5339af8d-b50d-4c74-87ce-775e806bb706.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Kepler Cheuvreux One Stop Shop Amsterdam

June 26, 2013

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Fresenius: 100 Years of Forward Looking Healthcare

Fresenius Group: A Decade of Consistent Growth

Fresenius Group: Attractive Long-term Shareholder Returns

20th consecutive dividend increase

Fresenius outperforms index

1Before one-time items Source: Bloomberg; dividends reinvested

Achieving Profitable Growth in Attractive Health Care Segments

Fresenius Medical Care is fully consolidated in the financial statements of Fresenius SE & Co. KGaA

Fresenius Group: Financial Results

l
S
a
e
s		 1
E
B
I
T		 1
i
N
t
e
n
c
o
m
e
/
Q
1
1
3		 €
4
8
9
0
m
,		 €
6
9
6
m		 €
2
2
4
m
G
h
t
t
t
t
r
o
w
a
c
o
n
s
a
n
t
c
u
r
r
e
n
c
y
r
a
e
s		 1
2
%		 6
%		 1
2
%
G
h
l
t
t
t
r
o
a
a
c
a
w
u
t
c
r
r
e
n
c
r
a
e
s
u
y		 1
1
%		 5
%		 1
2
%

1Before one-time items

Fresenius Group: Financial Results by Business Segment

/
Q
1
1
3		 i
F
e
s
e
n
s
r
u
d
i
l
C
M
e
c
a
a
e
r		 i
F
e
s
e
n
s
r
u
b
i
K
a		 i
F
e
s
e
n
s
r
u
l
i
H
e
o
s		 i
F
e
s
e
n
s
r
u
d
V
a
m
e
S
l
a
e
s
G
h
t
r
o
w		 \$
S
U
3
4
6
4
m
,
7
%		 €
2
0
1
6
m
,
1
5
%		 €
8
4
1
m
1
8
%		 €
8
1
4
m
2
3
%
E
B
I
T
G
h
t
r
o
w		 \$
U
S
9
3
4
m
%
2
-		 €
2
3
7
m
%
1
0		 €
8
7
m
%
2
8		 €
5
m
%
0

Fresenius Group: Distribution and Development of Net Income

Fresenius Kabi: Update Q1/13

    • Excellent start into the year
  • -7% organic sales growth; 20.0% EBIT margin excl. Fenwal
    • Europe
  • 2% organic growth on shortage-inflated Q1/12 base; Clinical Nutrition growth expected to accelerate
  • I.V. drug launch schedule backloaded in 2013, frontloaded in 2012
  • Expect mid single-digit growth in FY/2013
    • Asia-Pacific
  • -9% organic growth on top of strongest 2012 quarter
  • -Back to double-digit growth in FY/2013
    • North America
  • 14% organic growth strong start
  • Expect to maintain majority Propofol market share in 2013
  • Shortage situation unchanged gradual easing assumed
  • FY/2013: expect low to mid single-digit percent sales decrease – fully baked into Kabi 2013 guidance

Fresenius Helios: Update Q1/13

    • 5% organic sales growth – at upper end of guidance
    • Excellent EBIT margin increase to 11.2% (+140 bps) in established clinics
  • Wage contracts in place for >80% of HELIOS employees until end of 2013 and for ~40% until end of 2014; average increase of <3% p.a. fully in line with budget assumptions
  • Hospital transaction market awarded/acquired revenue YTD: ~€200 m; projects ~€120 million in revenue pending

HELIOS Endo Klinik Hamburg

Fresenius Vamed: Update Q1/13

    • Excellent quarter with 10% organic sales growth; EBIT fully in line with expectations
  • 15% organic sales growth in service business, now serving 355 health care facilities with >100,000 beds
    • Update on Italian market expansion – 5 new contracts for maintenance/technical management of medical equipment, serving ~3,800 hospital beds
  • Further expansion into CIS countries
  • €48 million turnkey project in Moscow
  • €11 million medical equipment contracts in Turkmenistan

International Diagnostic Center, Moscow

Fresenius Group: Financial Outlook by Business Segment Fully Confirmed

i
F
e
e
r
s
n
u
s
b
i
K
a		 S
l
h
t
a
e
s
g
r
o
w
c
c
S
l
h
t
i
a
e
s
g
r
o
w
o
r
g
a
n
c
i
E
B
I
T
l.
l
F
m
a
r
g
n
e
x
c
e
n
w
a
E
B
I
T
i
i
l.
F
l
m
a
r
g
n
n
c
e
n
w
a		 %
%
1
2
1
4
–
3
%
%
5
–
%
%
1
9
2
0
–
8
%
9
%
1
1
–
i
F
r
e
s
e
n
u
s
l
i
H
e
o
s		 S
l
h
t
i
a
e
s
g
r
o
w
o
r
g
a
n
c
E
B
I
T		 %
%
3
5
–
€
3
6
0
€
3
8
0
m
–
i
F
r
e
s
e
n
u
s
V
d
a
m
e		 S
l
h
t
a
e
s
g
r
o
w
E
B
I
T
h
t
g
r
o
w		 %
%
8
1
2
–
5
%
1
0
%
–

Fresenius Group: Financial Outlook Fully Confirmed

h
R
t
e
e
n
e
g
r
o
v
u
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 7
%
1
0
%
‒
1
i
h
N
t
t
e
n
c
o
m
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 %
2
%
7
1
‒

1 Net income attributable to shareholders of Fresenius SE &Co.KGaA adjusted for one-time integration costs of Fenwal (~€50 million pre-tax)

Attachments

Fresenius Group: Profit and Loss Statement

/
Q
1
1
3		 /
Q
1
1
2		 h
G
Q
t
r
o
w		 /
1
1
3
Y
Y
o
l
t
a
c
u
a
t
a
e
r
s		 t
t
o
c
n
s
a
n
t
a
e
r
s
4
8
9
0
,		 4
4
1
9
,		 %
1
1		 %
1
2
6
9
6		 6
6
1		 5
%		 6
%
1
6
3
-		 1
4
7
-		 %
1
1
-		 %
1
2
-
1
5
5
-		 1
5
6
-		 1
%		 0
%
2
2
4		 2
0
0		 %
1
2		 %
1
2

1 2013 adjusted for one-time integration costs of Fenwal of €7 million

2 Net income attributable to shareholders of Fresenius SE & Co. KGaA, 2013 adjusted for one-time integration costs of Fenwal of €5 million, 2012 adjusted for a non-taxable investment gain of €30 million at Fresenius Medical Care.

Fresenius Group: Consistent Cash Generation and Proven Track Record of Deleveraging

Cash Flow Development

€
m		 O
i
C
F
t
p
e
r
a
n
g		 C
a
p
e		 (
)
t
x
n
e		 1
h
l
F
C
F
r
e
e
a
s
o
w
/
Q
1
1
3		 i
L
T
M
M
a
g
n
r		 /
Q
1
1
3		 i
L
T
M
M
a
g
n
r		 /
Q
1
1
3		 i
L
T
M
M
a
g
n
r
1
3
2		 %
1
3
5		 (
)
5
6		 (
)
%
5
5		 7
6		 %
8
0
3
3		 7
2
%		 (
)
1
9		 (
)
%
5
2		 1
4		 3
%
2
0
4
5		 %
4
0		 (
)
1		 (
)
%
1
3		 4
4		 %
2
7
Co
/
te
rp
or
a
he
O
t
r		 5
-		 /
n
a		 (
)
1		 /
n
a		 6
-		 /
n
a
l.
F
M
C
ex
c		 2
0
5		 2
0
6
%
1		 (
)
7
7		 (
0
%
)
5		 2
8
1		 2
6
%
5
G
ro
up		 4
4
4		 1
1
9
%		 (
)
1
8
8		 (
)
5
0
%		 2
5
6		 6
9
%

1Before Acquisitions and Dividends

2Incl. FMC dividend

3Understated: 2.8% excluding €25 million of capex commitments from acquisitions

Fresenius Group: Debt and Interest Ratios

1Pro forma Fenwal

  • Adjusted for one-time costs (€6 million) related to the offer to the shareholders of RHÖN-KLINIKUM AG, for other one-time costs (€86 million) at Fresenius Medical Care as well as one-time integration costs (€7 million) at Fenwal
  • Pro forma including Liberty Dialysis Holdings, Inc., Damp Group, and Fenwal
  • 4Adjusted for one-time costs (€6 million) related to the offer to the shareholders of RHÖN-KLINIKUM AG and for other one-time costs (€86 million) at Fresenius Medical Care.

Fresenius Kabi: Strong Organic Sales Growth

€
m		 /
Q
3
1
1		 /
Q
2
1
1		 i
O
g
a
n
c
r
G
h
t
o
r
w
f
i
h
I
T
n
u
s
o
n
e
r
a
p
y		 2
5
0		 2
4
6		 %
5
I.
V
D
r
u
g
s		 4
6
0		 4
1
0		 1
3
%
C
l
i
i
l
i
i
N
t
t
n
c
a
r
o
n
u		 3
2
6		 3
1
6		 %
5
/
M
d
i
l
D
i
e
c
a
e
c
e
s
v
f
i
h
l
T
T
r
a
n
s
s
o
n
e
c
n
o
o
g
u
y		 2
2
4		 1
2
0		 %
1
-
l
l
T
t
o
a
s
a
e
s		 2
6
0
1
,		 0
9
2
1
,		 %
7

Fresenius Kabi: Strong Organic Sales Growth

€
m		 Q
/
3
1
1		 Q
/
2
1
1		 i
O
g
a
n
c
r
G
h
t
o
r
w
E
r
o
p
e
u		 5
1
7		 8
4
7		 %
2
N
h
A
i
t
o
r
m
e
r
c
a		 0
4
1		 2
9
2		 %
1
4
A
i
P
i
f
i
s
a
a
c
c
-		 2
2
3		 1
9
9		 %
9
i
i
/
f
i
L
A
A
t
a
n
m
e
r
c
a
r
c
a		 1
1
9		 1
1
4		 %
9
l
l
T
t
o
a
s
a
e
s		 2
6
0
1
,		 0
9
2
1
,		 %
7

Fresenius Kabi: EBIT Margin at Upper End of Guidance

€
m		 /
Q
1
1
3		 /
Q
1
1
2		 h
G
t
r
o
w
E
r
o
p
e
u
M
i
a
r
g
n		 8
4
1
6.
2
%		 9
6
1
9.
%
7		 %
1
3
-
h
i
N
A
t
o
r
m
e
r
c
a
M
i
a
r
g
n		 1
5
4
3
8.
4
%		 1
1
4
3
9.
0
%		 %
3
5
i
i
f
i
/
i
i
/
f
i
A
P
L
A
A
t
s
a
a
c
c
a
n
m
e
r
c
a
r
c
a
-
i
M
a
r
g
n		 6
5
%
1
9.
0		 5
8
%
1
8.
5		 %
1
2
C
d
C
R
D
t
t
&
o
r
p
o
r
a
e
a
n
o
r
p
o
r
a
e		 6
6
-		 3
5
-		 2
%
5
-
l
(
i
l.
l
)
T
E
B
I
T
F
t
o
a
n
c
e
n
a
w
M
i
a
r
g
n		 2
3
7
1
8
8
%		 2
1
5
1
9
7
%		 1
0
%
l
(
l.
l
)
T
t
E
B
I
T
F
o
a
e
c
e
n
a
x
w
i
M
a
g
n
r		 2
3
1
2
0
0
%		 2
1
5
1
9
7
%		 7
%

Fresenius Helios: Excellent Sales and EBIT Growth

€
m		 Q
/
3
1
1		 Q
/
2
1
1		 G
h
t
o
r
w
l
l
T
t
o
a
s
a
e
s		 8
4
1		 7
1
0		 1
8
%
E
B
I
T
E
b
l
i
h
d
l
i
i
f
l
i
t
t
s
a
s
e
c
n
c
p
o
r
o
o
i
M
a
r
g
n		 8
3
%
1
1.
2		 6
9
%
9.
8		 2
0
%
/
A
i
i
i
D
i
i
t
t
t
c
q
u
s
o
n
s
v
e
s
u
r
e
s
(
)
/
l
i
d
i
d
l
i
d
i
1
t
t
c
o
n
s
o
a
o
n
e
c
o
n
s
o
a
o
n
y
r
<		 4 1
-
l
T
E
B
I
T
t
o
a		 8
7		 6
8		 2
8
%
i
M
a
g
n
r		 0
3
%
1		 9
6
%

2012 adjusted for post-acute care clinic Zihlschlacht – transferred to Fresenius Vamed.

Fresenius Helios: 2012 Clinic Development Plan

Y i
e
a
r
s
n		 f
t
p
o
r		 l
i
o
o
1
<		 1 2 3 4 5 5
>		 l
T
t
o
a
N
f
l
i
i
o.
o
c
n
c
s		 6 2 1 - 6 4 3
1		 5
0
(
)
R
€
e
v
e
n
u
e
m		 2
2
7		 1
5
5		 3
6		 - 9
2
1		 2
9
4		 9
1,
1
0		 2,
8
1
4
T
t
a
r
g
e
(
)
E
B
I
T
D
A
i
%
m
a
r
g
n		 - 3.
0		 6.
0		 9.
0		 1
2.
0		 1
5.
0		 1
5.
0
(
)
E
B
I
T
D
A
€
m		 - 4.
7		 2.
2		 - 2
3.
0		 4
4.
1		 2
8
6.
5		 3
6
0.
5
d
R
t
e
o
e
p
r
(
)
i
%
E
B
I
T
D
A
m
a
r
g
n		 - 3.
3
-		 7.
4		 - 1
1.
0		 1
5.
4		 1
7.
5		 1
4.
1
(
)
E
B
I
T
D
A
€
m		 1.
1
-		 5.
2
-		 2.
7		 - 2
1.
2		 4
5.
1		 3
3
4.
8		 3
9
7.
5
N
f
l
i
i
t
t
o.
o
c
n
c
s
a
r
g
e
>		 - 1 1 - 3 3 1
9		 2
7
N
f
l
i
i
t
t
o.
o
c
n
c
s
a
r
g
e
<		 - 1 - - 3 1 2
1		 1
7

IFRS

Fresenius Vamed:

Excellent Sales Growth, EBIT Fully in Line with Expectations

€
m		 Q
/
3
1
1		 Q
/
2
1
1		 G
h
t
o
r
w
j
b
i
P
t
r
o
e
c
u
s
n
e
s
s		 8
2		 7
7		 %
6
S
i
b
i
e
r
v
c
e
u
s
n
e
s
s		 0
2
1		 2
7		 2
%
4
l
l
T
t
o
a
s
a
e
s		 8
1
4		 9
1
4		 2
3
%
l
T
t
E
B
I
T
o
a		 5 5 0
%
i
M
a
g
n
r		 2
7
%		 3
4
%
1
d
i
k
O
t
r
e
r
n
a
e		 9
3		 1
0
4		 1
1
%
-
1
d
b
k
l
O
r
e
r
a
c
o
g		 8
9
9		 2
8
9
7		 1
%

1Project business only

December 31, 2012

2012 adjusted for post-acute care clinic Zihlschlacht

Share Information

Share key facts

Number of shares1 178,307,893 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de

WKN / ISIN 578560 / DE0005785604

ADR key facts

Ticker symbol FSNUY Exchange OTC-market Depositary bank Deutsche Bank

Ratio 8 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053Structure Sponsored Level I ADR

1As of April 30, 2013

Financial Calendar

3
0
0
2
0
3
7
1		 t
R
h
l
f
2
0
3
t
1
1
s
e
p
o
r
o
n
a
0
2
0
3
5
1
1
1		 d
t
R
3
2
0
3
t
1
t
1
s
r
e
p
o
r
o
n
q
u
a
r
e
r
–

Contact

Birgit Grund SVP Investor Relations Fresenius SE & Co. KGaA Telephone: +49 6172 608-2485 e-mail: [email protected]

For further information and current news: http://www.fresenius.com

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.